Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal Etanercept for Discoid Lupus Erythematosus
NCT02656082Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Feb 2016
- Primary completion
- Dec 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etanercept in discoid lupus erythematosus (DLE), sponsored by University of Leeds. Primary endpoint: Proportion of patients achieving a reduction in modified limited Score of Activity and Damage in Discoid Lupus Erythematosus (SADDLE) score by 20% at 12 weeks. Started Feb 2016; status: completed.
02
Drugs
etanercept
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT02656082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656082.